Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics Inc (NQ: IOVA )

8.800 +0.060 (+0.69%)
Streaming Delayed Price Updated: 3:52 PM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Iovance Biotherapeutics Inc

< Previous 1 2 3 4 5 Next >
Gas Price Predictions: How Much Will Gas Cost Over Memorial Day Weekend?
Anyone planning to travel over the Memorial Day Weekend is going to want to check out the latest gas price predictions. 
Via InvestorPlace
Why Is Iovance Therapeutics (IOVA) Stock Down 45% Today?
Iovance Therapeutics (IOVA) stock is falling hard on Friday following the release of clinical trial data for its melanoma treatment. 
Via InvestorPlace
Mid-Morning Market Update: Markets Open Higher; US Goods Trade Deficit Narrows In April
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're starting the final day of trading for the week with a breakdown of the biggest pre-market stock movers for Friday! 
Via InvestorPlace
4 Analysts Have This to Say About Iovance Biotherapeutics
Within the last quarter, Iovance Biotherapeutics (NASDAQ:IOVA) has observed the following analyst ratings: 
Via Benzinga
Iovance Receives FDA Allowance For IOV-4001 Study In Two Advanced Cancers
 
Via Benzinga
20 Stocks Moving in Friday's Pre-Market Session
Gainers Adicet Bio, Inc. (NASDAQ: ACET) rose 16% to $11.90 in pre-market trading after reporting positive clinical update from ADI-001 Phase 1 Trial in relapsed/refractory Non-Hodgkin’s Lymphoma. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 
Via Benzinga
Iovance Biotherapeutics Just Flashed A Bullish Sign Despite Melanoma Drug Delay
This biotech stock is mounting a two-day recovery and is well above its 50-day line. 
Via Investor's Business Daily
The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Iovance Outlines Frontline Melanoma Strategy For Lifileucel / Pembrolizumab Combo Therapy
The  
Via Benzinga
All The Stocks That Moved Wednesday From CNBC's 'Fast Money: Halftime Report'
CNBC's "Fast Money: Halftime Report" delivers market-moving news to investors. The commentary delivered by hosts of the show often move the stocks mentioned.... 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
Recap: Iovance Biotherapeutics Q4 Earnings
Iovance Biotherapeutics (NASDAQ:IOVA) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... 
Via Benzinga
Iovance's Lifileucel Combo Shows Encouraging Response Rates In Advanced Cancers
Iovance Biotherapeutics Inc (NASDAQ: IOVA) has announced data for lifileucel in combination with Merck Co Inc's (NYSE: MRK) Keytruda (pembrolizumab)... 
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
Iovance Shares Tumble After Cell Therapy Data From Lung Cancer Trial
Iovance Biotherapeutics Inc (NASDAQ: IOVA) has announced additional data for LN-145 in patients with metastatic non-small cell lung cancer (mNSCLC) enrolled in... 
Via Benzinga
70 Biggest Movers From Friday
Gainers Everspin Technologies, Inc. (NASDAQ: MRAM) shares surged 63.2% to close at $10.74 on Friday after the company reported better-than-expected Q3 results and issued Q4... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers SOC Telemed (NASDAQ:TLMD) stock increased by 30.04% to $2.77 during Friday's regular session. The current volume of 1.9 million shares is 238.17% of SOC... 
Via Benzinga
48 Stocks Moving In Friday's Mid-Day Session
Gainers Everspin Technologies, Inc. (NASDAQ: MRAM) shares climbed 41% to $9.28 after the company reported better-than-expected Q3results and issued Q4 sales guidance above... 
Via Benzinga
Iovance Biotherapeutics, inc (IOVA) Q3 2021 Earnings Call Transcript
IOVA earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Corvus Pharmaceuticals (NASDAQ:CRVS 
Via Benzinga
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
Why Iovance Is Up Nearly 11% Today
Investors are starting to connect some drug development dots... with a little help. 
Via The Motley Fool
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Cathie Wood's Ark ETFs Underperformed The Broader Market In Q2, With Workhorse, Virgin Galactic, Coinbase, Teladoc Taking Big Toll
ARK Invest, the New York-based investment management firm led by the popular money manager Cathie Wood, saw its five actively managed exchange-traded funds and two self-indexed... 
Via Benzinga
Why Iovance Biotherapeutics Soared 40% In June
The biopharma outfit has put some red flags in the rearview mirror, and sees a plausible approval on the horizon. 
Via The Motley Fool
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.